JPRN-UMIN000049792已完成Unknown
An open-label,\x{00a0}single-arm study to evaluate the efficacy of yogurt containing probiotic bifidobacterium LKM512 and arginine on vascular endothelial function and blood pressure - An open-label,\x{00a0}single-arm study to evaluate the efficacy of yogurt containing probiotic bifidobacterium LKM512 and arginine on vascular endothelial function and blood pressure
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 35years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Participants who take a medicine, or visit the hospital for disease 2. Participants who are undergoing diet therapy or exercise therapy under medical supervision 3. Participants with current or past history of serious illness 4. Participants who can't stop taking over-the-counter drugs, quasi-drugs, and/or functional foods (including Food for Specified Health Uses or Foods with Function Claims) 5. Participants who have drug or food allergies 6. Participants who donated component blood or 200 ml of whole blood within 1 month prior to the start of this study 7. Participants who donated 400 ml of whole blood within 4 months prior to the start of this study 8. Participants who have participated or are participating in other clinical study within one month prior to the obtaining consent, or those who plan to participate during the study period 9. Participants who are pregnant or breastfeeding, or those who might become pregnant during the study period 10. Participants who drink a lot of alcohol (60 g/day, the volume of pure alcohol) 11. Participants who have an irregular life rhythm, such as those who have extremely irregular eating habits, those who are shift workers, or those who work the graveyard shift 12. Inappropriate cases evaluated by medical doctors
研究者
相似试验
招募中
1 期
An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infection.CTIS2024-510663-34-00Glaxosmithkline Research & Development Limited12
进行中（未招募）
1 期
An open label, single arm study to evaluate the pharmacokinetics, safety and tolerability of intravenous (IV) zanamivir in hospitalised neonates and infants under 6 months of age with confirmed influenza infectioInfluenzaEUCTR2019-001588-63-NLGlaxoSmithKline Research & Development Limited12
进行中（未招募）
1 期
An open label, single arm study to evaluate the pharmacokinetics, safety and tolerability of intravenous (IV) zanamivir in hospitalised neonates and infants under 6 months of age with confirmed influenza infectioInfluenzaEUCTR2019-001588-63-PLGlaxoSmithKline Research & Development Limited12
尚未招募
2 期
An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous |(IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infectioInfluenzaNL-OMON50842GlaxoSmithKline3
进行中（未招募）
1 期
An open label, single arm study to evaluate the pharmacokinetics, safety and tolerability of intravenous (IV) zanamivir in hospitalised neonates and infants under 6 months of age with confirmed influenza infectioInfluenzaEUCTR2019-001588-63-GBGlaxoSmithKline Research & Development Limited12